Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance

PLoS One. 2018 Jun 28;13(6):e0199531. doi: 10.1371/journal.pone.0199531. eCollection 2018.

Abstract

Objectives: We assess the epidemiology and risk factors for mortality of bloodstream infection (BSI) in patients with acute leukemia (AL).

Methods: Prospectively collected data of a cohort study from July 2004 to February 2016. Multivariate analyses were performed.

Results: 589 episodes of BSI were documented in 357 AL patients, 55% caused by gram-positive bacteria (coagulase-negative staphylococci 35.7%, Enterococcus spp 10.8%) and 43.5% by gram-negative bacteria (E. coli 21%, PA 12%). We identified 110 (18.7%) multidrug-resistant (MDR) microorganisms, especially MDR-Pseudomonas aeruginosa (7%) and extended-spectrum beta-lactamase producing Enterobacteriaceae (7%). The 30-day mortality was 14.8%. Age (OR 3.1; 95% CI 1.7-5.7); chronic lung disease (4.8; 1.1-21.8); fatal prognosis according to McCabe index (13.9; 6.4-30.3); shock (3.8; 1.9-7.7); pulmonary infection (3.6; 1.3-9.9); and MDR-PA infections with inappropriate treatment (12.8; 4.1-40.5) were related to mortality. MDR-PA BSI was associated to prior antipseudomonal cephalosporin use (9.31; 4.38-19.79); current use of betalactams (2.01; 1.01-4.3); shock (2.63; 1.03-6.7) and pulmonary source of infection (9.6; 3.4-27.21).

Conclusions: MDR organisms were commonly isolated in BSI in AL. Inappropriate empiric antibiotic treatment for MDR-PA is the primary factor related to mortality that can be changed. New treatment strategies to improve the coverage of MDR-PA BSI should be considered in those patients with risk factors for this infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bacteremia / complications*
  • Bacteremia / microbiology
  • Bacteremia / mortality*
  • Bacteremia / therapy
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Leukemia / complications*
  • Leukemia / microbiology
  • Leukemia / mortality*
  • Leukemia / therapy
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Risk Factors

Grants and funding

Dra. Carolina Garcia-Vidal has received INTENSIFICACIÓ Grant- a grant supported by the Catalan Health Agency [PERIS (Pla estratègic de recerca i innovació en salut – ‘Strategic Plan for Research and Innovation in HealthCare’)]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.